Erdafitinib

厄达替尼

Report date: 2026/02/14 20:00:22
NMEFirst In Class

Base Information

Drug NameErdafitinib
Drug Alias NameErdafitinibumBalversa博珂890E37NHMVG-024 +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFibroblast growth factor receptor 4 antagonistsFibroblast growth factor receptor 3 antagonistsFibroblast growth factor receptor 1 antagonists +[4] 
TargetsFibroblast growth factor receptor 4Fibroblast growth factor receptor 1Fibroblast growth factor receptor 3 +[4] 
Therapy Area/IndicationsBone metastasesMetastatic breast cancerSolid tumours +[39] 
Global Approved IndicationsUrologic NeoplasmsCarcinoma, Transitional Cell
Approved Indications in ChinaCarcinoma, Transitional Cell
Original Approved Country/TerritoryUnited States
Original Approved Date2019/04/12
Country/TerritoryCzechiaBelgiumBulgaria +[36] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAstex Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesJohnson & Johnson (China) Investment LtdJanssen-Cilag International NvCatalent Pharma Solutions +[12] 
Inactive CompaniesJanssen Cilag SpacompanyJohnson & Johnson Pharmaceutical LtdThe University Of Texas MD Anderson Cancer Center +[4] 
Active IndicationsMetastatic breast cancerSolid tumoursXanthogranuloma, Juvenile +[31] 
Inactive IndicationsBone metastasesHepatic InsufficiencyProstatic Neoplasms, Castration-Resistant +[8] 

Other Information

ATC CodeL01XE
Related LinksWikipediaDrugBankKEGG